Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

THRIVE

Financiado

Cerrado

TUMOUR HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS

"Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatob... ver más

30/11/2028

Líder desconocido

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto Líder desconocido

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-11

HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minima... Expected Outcome:Proposals under this topic should aim to deliver results that are directed and tail...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 59 meses Fecha Inicio: 2023-12-11
Fecha Fin: 2028-11-30

Líder del proyecto Líder desconocido

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma (HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%) with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations, resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease progression after surgical intervention and adjuvant chemotherapy. THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding at-risk populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from 8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors (i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples). THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such as the UNCAN.eu platform, and by influencing policymakers and health professionals. This action is part of the Cancer Mission cluster of projects on Understanding (tumour-host interactions)""."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores